By Vivonyx · Last reviewed: October 2026
Low back pain is one of the most common reasons people look into stem cell injections. When the pain is tied to a worn spinal disc, the idea sounds logical: put cells into the disc and see if it rebuilds. The research is more mixed than the marketing, and that mix is worth understanding.
A quick look at the disc
Your spinal discs sit between the bones of your spine like small cushions. Each one has a tough outer ring and a gel-like center. With age, the center tends to lose water and the disc can thin, which doctors call degenerative disc disease. Discs have very little blood supply, so they don't repair themselves well.
The small trial that got people excited
In a Spanish study, 24 people with chronic back pain and disc degeneration were randomly assigned to either donor bone marrow MSCs injected into the disc or a sham injection [1]. The researchers reported faster improvement in pain and function scores in the cell group. But they also noted the improvement "seemed restricted to a group of responders" that made up about 40% of the people treated. Disc scores on MRI improved in the cell group and worsened in the controls.
A mid-size trial with mixed signals
A U.S. trial of 100 people tested donor mesenchymal precursor cells (a type of MSC) injected into a single painful disc, with or without hyaluronic acid, against control injections [2]. It's registered as NCT01290367 [3]. The cell groups did better on several pain and disability measures "at various time points" over three years.
What didn't change: disc scores on imaging. There were no significant differences between groups in the MRI grading. The study was funded by Mesoblast, the company that makes the cells. That doesn't make it wrong, but it's worth knowing.
The big trial that missed its main goal
A larger follow-up trial enrolled 404 people at 49 sites [4]. The trial's primary goal was not met for either cell group compared with control, and none of the secondary goals were met across all participants either.
There were some positive signals. The group that got cells plus hyaluronic acid had lower pain at 12 and 24 months, and results looked stronger in a pre-planned subgroup of people whose pain had lasted less than about 68 months. Subgroup findings can point to who might respond, but they need to be confirmed in a new trial before anyone can rely on them. This study was also company-funded.
Get the next article in your inbox
One short email when a new research article goes up. No spam, unsubscribe anytime.
What about your own bone marrow?
Some clinics use bone marrow concentrate from the patient's own hip. One study followed 26 people for three years after this kind of injection and reported lower pain scores on average [5]. But there was no control group, so it's hard to separate the injection's effect from time, other care, or the natural ups and downs of back pain. Treat studies like this as early and uncontrolled.
The honest limits
- Few large trials. The biggest one didn't meet its primary goal.
- Different products. Donor marrow cells, precursor cells, and your own marrow concentrate are not interchangeable, and results from one don't transfer to another.
- Imaging and pain don't always match. A disc can look better without feeling better, and the reverse.
- Wharton's jelly cells have not yet been tested for disc disease in a large randomized trial that we could find. If you see that claim, ask for the study.
Where the FDA stands
The FDA's consumer guidance notes that stem cell products have not been approved for orthopedic conditions like back pain, outside of clinical trials [6]. That means the research is still underway, not that the question is settled. For more on what "approved" means, see our post Is Stem Cell Therapy FDA Approved?.
The bottom line
Back pain research shows real interest and some encouraging signals, along with a large trial that didn't hit its main target. The fair summary is "promising in places, not proven." If you're weighing any option, our 8 questions to ask before stem cell therapy can help, and The Science covers how MSCs are thought to work. You can also compare this with the knee research in Stem Cells vs PRP for Knee Arthritis.
FAQ
Can stem cells regrow a spinal disc?
Not shown in humans so far. One small trial reported better MRI grading, but a 100-person trial found no difference in disc imaging between groups [1][2].
Did the large back pain stem cell trial work?
Its primary goal wasn't met in all participants. Some pain measures and a pre-planned subgroup looked better, which still needs confirming [4].
Is stem cell therapy for back pain FDA approved?
No stem cell product is FDA-approved for back pain or disc disease. Research continues in clinical trials [6].
Are bone marrow and donor cells the same thing?
No. They're different products studied in different trials, so results from one can't be assumed for another.
Have a question about a study? Email hello@vivonyx.com or try our AI assistant. A real person reads every email.
Related reading
Vivonyx is education only and isn't medical advice. Talk with your own clinician about your situation.
References
- Noriega DC, et al. Intervertebral disc repair by allogeneic mesenchymal bone marrow cells: a randomized controlled trial. Transplantation. 2017;101(8):1945-1951. PMID: 27661661. https://pubmed.ncbi.nlm.nih.gov/27661661/
- Amirdelfan K, et al. Allogeneic mesenchymal precursor cells treatment for chronic low back pain associated with degenerative disc disease: a 36-month study. Spine J. 2021;21(2):212-230. PMID: 33045417. https://pubmed.ncbi.nlm.nih.gov/33045417/
- ClinicalTrials.gov. Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain. NCT01290367. https://clinicaltrials.gov/study/NCT01290367
- Beall DP, et al. Efficacy and safety of allogeneic mesenchymal precursor cells with and without hyaluronic acid for chronic low back pain: a 36-month study. Spine J. 2025;25(9):1997-2013. PMID: 40174800. https://pubmed.ncbi.nlm.nih.gov/40174800/
- Pettine KA, et al. Autologous bone marrow concentrate intradiscal injection for degenerative disc disease with three-year follow-up. Int Orthop. 2017;41(10):2097-2103. PMID: 28748380. https://pubmed.ncbi.nlm.nih.gov/28748380/
- U.S. FDA. Important Patient and Consumer Information About Regenerative Medicine Therapies. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies